World Parkinson Congress Blog

Posts in Clinical Science

Patient-Centered Care: A Paradigm Whose Time Has Come

Patient-Centered Care: A Paradigm Whose Time Has Come

by Laurie K Mischley ND, PhD, MPH

Clinical ScienceLaurie K. Mischley ND, PhD, MPHOctober 8, 2018three Comment

Alpha-Synuclein Biomarker Development for PD Research

Alpha-Synuclein Biomarker Development for PD Research

by Leonidas Stefanis, MD, PhD

Clinical ScienceLeonidas Stefanis MD, PhDSeptember 21, 2018three, Alpha-Synuclein, parkinson's disease, ResearchComment

Why I Am Excited and Optimistic About the Prospects of Finding Neuroprotective Therapies in Parkinson's Disease

Why I Am Excited and Optimistic About the Prospects of Finding Neuroprotective Therapies in Parkinson's Disease

by Tanya Simuni, MD

Clinical ScienceTanya Simuni, MDAugust 15, 2018neuroprotection, Disease Modification, parkinson's disease, threeComment

Etiquette in Clinical Research: Some Do's and Don'ts When You Sign Up

Etiquette in Clinical Research: Some Do's and Don'ts When You Sign Up

By Simon Stott, PhD

Clinical ScienceSimon Stott, PhDAugust 13, 2018clinical, research, rules, study, three Comment

Parkinson's Research - Are We Standing Still or Making Progress?

Parkinson's Research - Are We Standing Still or Making Progress?

By Lisa M. Shulman, MD

Clinical ScienceLisa M. Shulman, MDAugust 6, 2018three, Research, Parkinson's DiseaseComment

Why Does It Take So Long?

Why Does It Take So Long?

By Tom Foltynie, PhD, MD, MRCP

Clinical ScienceTom Foltynie PhD, MD, MRCPJuly 30, 2018three Comment

Why Have We Failed In Our Attempts To Develop A Neuroprotective Therapy For Parkinson's? How Can We Improve This Situation?

Why Have We Failed In Our Attempts To Develop A Neuroprotective Therapy For Parkinson's? How Can We Improve This Situation?

by A. Jon Stoessl CM, MD FRCPC

Clinical ScienceA. Jon Stoessl CM, MD FRCPCJune 18, 2018three, neuroprotection, Alpha-Synuclein, GBAComment

Swallow Problems May Start Early

Swallow Problems May Start Early

by Michelle R. Ciucci, PhD, CCC-SLP

Clinical ScienceMichelle R. Ciucci PhD, CCC-SLPJune 11, 2018three, swallow, swallowing, dysphagia, droolingComment

Misperceptions

Misperceptions

by Joseph H. Friedman, MD

Clinical ScienceJoseph H. Friedman, MDMay 29, 2018three, drooling, speech, driving, spacial perceptionComment

When PD Starts: Can We Diagnose Parkinson Disease Before The Onset Of Motor Symptoms?

When PD Starts: Can We Diagnose Parkinson Disease Before The Onset Of Motor Symptoms?

by Eduardo Tolosa, MD

Clinical ScienceEduardo Tolosa, MDMay 14, 2018Pre-motor symptoms, Prodromal, threeComment

"Good Days and Bad Days" with Parkinson's Disease

"Good Days and Bad Days" with Parkinson's Disease

by Peter A. LeWitt, MD

Clinical SciencePeter A. LeWitt, MDMay 7, 2018Levodopa, three Comments

Vision Disorders in Parkinson's Disease and Clinical Implications

Vision Disorders in Parkinson's Disease and Clinical Implications

by Dan Gold DO & Andrew Billnitzer MD, MPH

Clinical ScienceDan Gold DOMay 1, 2018three, vision, dry eyeComment

The Puzzling Features of Fatigue

The Puzzling Features of Fatigue

by Joseph H. Friedman, MD

Clinical ScienceJoseph H. Friedman, MDApril 13, 2018fatigue, twoComment

What is the Report Card on Symptomatic, Cure-Based and Disease Modifying Strategies for Parkinson’s Disease?

What is the Report Card on Symptomatic, Cure-Based and Disease Modifying Strategies for Parkinson’s Disease?

by Michael Okun, MD

Clinical ScienceMichael Okun, MDApril 5, 2018Cure, disease modification, Therapies, twoComment

The Future of iPS Cell Transplantation in Parkinson’s Disease

The Future of iPS Cell Transplantation in Parkinson’s Disease

by Ryuji Kaji MD, PhD

Clinical ScienceRyuji Kaji MD, PhDMarch 16, 2018Stem Cells, Dopamine, twoComment

Could Dogs be the Portal to Early Detection & Prevention?

Could Dogs be the Portal to Early Detection & Prevention?

by Laurie K. Mischley, ND PhD MPH

Clinical ScienceLaurie K. Mischley ND, PhD, MPHFebruary 21, 2018Parkinson, canine-based, PD screening, biomarkers, parkinson's disease, two Comments

Frequently Asked Questions about the Cognitive and Behavior Effects of Deep Brain Stimulation

Frequently Asked Questions about the Cognitive and Behavior Effects of Deep Brain Stimulation

by Alexander I. Tröster, PhD

Clinical ScienceAlexander I. Troster, PhDFebruary 2, 2018Deep Brain Stimulation, Cognition, Memory, Emotion, Quality of Life, twoComment

Re-purposing Old Drugs for New Treatments for Parkinson's Disease: Can an Asthma Drug Slow Progression of PD

Re-purposing Old Drugs for New Treatments for Parkinson's Disease: Can an Asthma Drug Slow Progression of PD

by John G. Nutt, MD

Clinical ScienceJohn G. Nutt, MDJanuary 31, 2018Repurposing drugs, Albuterol, Alpha-Synuclein, twoComment

Planning For Prevention. It Is Time.

Planning For Prevention. It Is Time.

by Michael Schwarzschild, MD PhD

Clinical ScienceMichael Schwarzschild MD, PhDJanuary 3, 2018Prevention, neuroprotection, clinical trials, genetics, Prodromal, LRRK2, twoComment

Why We Are Excited About MRI of Neuromelanin to Predict Parkinson's

Why We Are Excited About MRI of Neuromelanin to Predict Parkinson's

by David Sulzer, PhD & Luigi Zecca MD, PhD

Clinical ScienceDavid Sulzer, PhDNovember 27, 2017MRI, Diagnosis, Diagnostics, early screening, neuromelanin, MRi, neuroimaging, twoComment